Salarius Pharmaceuticals Presents Compelling Data in Two SP3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

HOUSTON, April 20, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced the presentation of two posters related to the company’s novel molecular glue, SP-3164, at…Read More

Leave a Reply

Your email address will not be published. Required fields are marked *